Compare Organon & Co. Common Stock (OGN) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs SAP SE — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while SAP SE trades at $222.17 (market cap $254.11B). The key difference: SAP SE is far larger — about 70.2× Organon & Co. Common Stock's market cap, and SAP SE pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and SAP SE for 118 Days on average.
| OGN | SAP | |
|---|---|---|
Market Cap | $3.62B | $254.11B |
Volume | 2,892,999 | 2,139,071 |
Sector | Health | Technology |
52-Week High | $13.81 | $280.46 |
52-Week Low | $5.70 | $146.38 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $11.04B | $252.86B |
Dividend Yield | 0.58% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SAP trades at $220.49, up 1.21% today, with a bullish technical outlook supported by moving averages and a consensus price target of $253.60. The company reported strong revenue growth to $36.80B in 2025 and a net income margin of 20.41%, though Q2 2026 EPS missed expectations. Recent news highlights AI-driven cloud revenue growth and partnerships, while cash flow trends show variability with a net outflow of $1.39B in 2025.
The stock presents upside potential based on analyst targets and robust fundamentals, but risks include competitive pressures in enterprise software and execution challenges in AI integration. Investors should weigh solid profitability against valuation multiples like a P/E of 29.48, which may limit near-term gains if growth moderates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
